INTRODUCTION
============

With industrial advancement, a demand for the measurement of environmental pollution-related hazardous substances to the body has been on the rise. It's been known that environmental pollutants such as heavy metal cause a problem in immune system functions or in various physiological functions. They can also disease susceptibility including cancer. Because people can be exposed to heavy metals in diverse routes, it is desirable to estimate the exact exposure levels and evaluate risk using biological indexes in order to figure out the exposure to heavy metals [@B013]; [@B016]; [@B010]; Moyer, 1999; AACC, 1996; [@B007]; [@B001]; Shaw *et al*., 2001).

With the aging of population, Alzheimer's disease prevalence has dramatically increased by age. Specifically, it stayed at 7\~10% among those aged 65\~74, 18\~20% among the aged 75\~84 and 35\~40% among those aged 85 or older [@B011]. It appears that the number of the patients with Alzheimer's disease would further increase.

In Korea, about 8.4% of the aged population (65 or older) is suffering from Alzheimer's disease. According to a study on the number of the patients with Alzheimer's disease in urban and rural areas, it is forecasted that it would increase up to 730,000 in 2020 and 1.95 million in 2050. The heavy metal poisoning was included in 'non-occupational sentinel and environmental diseases' designated by the US Center for Disease Control and Prevention to achieve the national health goal for year 2000 [@B017]. The US National Institute of Environmental Health Sciences (NIEHS) also mentioned lead poisoning and mercury poisoning as leading heavy metal-related environmental diseases [@B018]. In Korea, the Ministry of Environment pointed out Pb, Hg and Cd as hazardous materials.

In foreign countries, correlations between heavy metal and Alzheimer's disease have already been discussed and analyzed. In Korea, however, it's been hard to find a study related to the said topic. Instead, there have been studies on evaluation of the exposure to heavy metal in the blood or urine. According to foreign references, there has been no consistency in correlations between heavy metal and Alzheimer's disease.

In terms of a trace metal analysis method on biological specimens, Graphite Furnace Atomic Absorption Spectrometry (GFAAS) has been used for a long time. However, this method is partially limited due to high LOD, long analysis time, poor reproducibility and difficult operations. Therefore, Inductively Coupled Plasma/Mass Spectrometry (ICP/ MS) through which multiple items can be analyzed at the same time with low LOD has become more popular as an alternative of the GFAAS. Recently, there have been a lot of studies on the analysis of blood and biological indexes using ICP/MS. Since 2000, ICP/MS has been used as a monitoring analysis method in the U.S. and Europe [@B010]; Moyer, 1999; AACC, 1996; [@B007]; [@B001].

Direct Mercury Analyzer (DMA), one of the mercury analysis methods, is the apparatus to measure mercury in liquid (or solid) specimen in a fast, precise and convenient way. Under this method, mercury can be analyzed without sample preparation (acid digestion). Therefore, the time for sample preparation can be saved. The mercury which is oxidized in the solid or soluble sample by the heat which is precisely adjusted in the furnace is thermally and chemically degraded after drying process [@B008].

This study has attempted to establish an analysis method after conducting a validation on heavy metals (Pb, Cd and Hg) in the blood and serum of the patients with Alzheimer's disease using ICP-MS and Gold amalgamation and figure out correlations between heavy metal and Alzheimer's disease after analyzing the distribution of heavy metal (Pb, Cd and Hg) concentration and the correlations between a control group and Alzheimer's disease group in Korea.

MATERIALS AND METHODS
=====================

***Sampling.*** For this study, blood and serum were sampled from a control group (130 people) and Alzheimer's disease group (80 patients) in a hospital in Seoul. Because the general public in which concentration would be low are included in the samples, in particular, the effect of pollution which can occur during sampling and inspection on the results of analysis is relatively more important. To minimize the possibility of this kind of pollution, therefore, blood was sampled using disposable stainless steel needles after disinfecting the part in which blood was collected with 70% isopropyl alcohol. Then, the blood was sampled in Serum Separation Tube (SST, 5 m*l* each) for the analysis of serum. The Heparin tube was vertically stirred 4 to 6 times to make anticoagulant well mixed with blood. The serum was centrifuged at 2500 rpm for five (5) minutes, and the collected samples were kept at −70℃ until they were used in the test. Right before the analysis, they were stored at −24℃ and then at 4℃. After that, the final test was performed.

***Reagents.*** The standard solution of each target material (Pb and Cd) used in this study is Perkin-Elmer (New york, USA)'s multi-element calibration standard 3 (10 mg/kg). In case of the standard solution of Hg, Kinto Chemical (Tokyo, Japan)'s solution (1,000 mg/*l*) was used.

In terms of distilled water used in sample preparation and analysis, the triple distilled water of Mili-Q system (Milipore, MA; USA) was used. For nitric acid (67% v/v) and hydrogen peroxide (31% v/v) which would be used in the Microwave Digestion System, DONGWOO FINE-CHEM's semiconductor level was used.

For the accurate validation on the analysis method, a certificated reference material (Lyphochel^®^ Whole Blood Metals Control Level 1 manufactured by Biorad (California, USA) was used.

***Sample preparation.*** The blood and serum of a control group and Alzheimer's disease group were kept at −70℃. Right before the analysis, they were moved and stored at −24℃ and later at 4℃. Before the test, a roller mixer was used for 1\~2 hour(s) for homogenization and prevention of coagulation.

To analyze Pb and Cd in the homogenized blood and serum with ICP-MS, 1 m*l* of specimen was put into a Teflon vessel using the microwave digestion system. Then, the lid was closed after adding 2 m*l* of nitric acid and 0.2 m*l* of hydrogen peroxide. Then, after inserting the vessel into the safety shield, it was dissolved at 400W for five (5) minutes and at 800 W for another five minutes ([Table 1](#T001){ref-type="table"}).

###### Scheme of microwave digestion system and ICP-MS

![](toxicr-28-93-i001)

***Determination.*** As a microwave digestion system used for pre-treatment of Pb and Cd in this study, the system manufactured by Milestone (Sorisole, Italy) has been used. Regarding Inductively Coupled Plasma - Mass Spectrometry (ICP-MS), the system manufactured by Perkin-Elmer (New York, USA) was used for measurement. Regarding the gold-Amalgamated Direct Mercury Analyzer (DMA)- 80, the system manufactured by Milestone (Sorisole, Italy) was used for analysis of Hg. The analysis conditions for each system were stated in the tables below ([Tables 2](#F002){ref-type="fig"}, [3](#F003){ref-type="fig"}).

###### 

Instrumental parameters for ICP-MS

  ------------------------- ---------------------------
  Descriptions              Conditions
                            
  R.F. generator            Free-running type, 40 MHz
  R.F. power                1500W
  Plasma gas flow rate      18.0 *l*/min.
  Auxiliary gas flow rate   1.50 *l*/min.
  Nebulizer gas flow rate   1.00 *l*/min.
  Lens Voltage              8.5 V
  Nebulizer                 Concentric type
  Spray chamber             Cychronic type
  Torch                     Demountable
  Interface cones           Platinum
  Quadrupole chamber        1 × 10^−6^ torr
  Dwell time                600 ms
  Pb/Mass                   208, 206
  Cd/Mass                   114, 112
  ------------------------- ---------------------------

###### 

Instrumental parameters for Mercury Analyzer (Gold amalgamation)0

  ------------------ -------------------------- ----------------
  Descriptions       Conditions                 
                                                
  Wavelength         253.65 nm                  
  Interface filter   254 nm                     
  Detector           Silicon UV photodetector   
  Catalyst           Platinum                   
  Drying             Blood                      300 ℃, 120 sec
  Serum              300 ℃, 60 sec              
  Decomposition      Blood                      850 ℃, 280 sec
  Serum              850 ℃, 180 sec             
  Purge              60 sec                     
  Amalgam            12 sec                     
  record             30 sec                     
  ------------------ -------------------------- ----------------

![Calibration curve of Pb and Cd in Blood by ICP-MS.](toxicr-28-93-g001){#F001}

***Method validation.*** In this study, validation was performed through of analysis equipment between ICP-MS for analysis of blood and serum. For method validation, validation parameters were selected, and a validation test was conducted. The validation parameters include linearity, sensitivity, selectivity, precision, accuracy and Limit Of Detection (LOD) & Limit Of Quantification (LOQ). If there is a possibility of matrix effect, the difference of slope between two calibration curves by adding standard reagent. In this study, the analysis method was validated using spiked sample and certified reference materials [@B015].

The LOD and LOQ were calculated using the sigma method (LOD: 3σ, LOQ: 6σ) [@B004]. The LOD and LOQ which considered dilution factor were calculated as follows; MDL = dilution factor × LOD/MQL = dilution factor × LOQ.

RESULTS
=======

***Validation of analysis methods of blood lead and cadmium.*** In this study, validation by analysis method of blood lead and cadmium by ICP-MS.

In terms of the validation of blood lead level analysis, first of all, MDL was 0.55 μg/d*l* while MQL was 1.10 μg/d*l* in ICP-MS. In terms of calibration curve, good linearity was observed (0.9993). Precision which was calculated through %RSD was 1.23% while recovery was 90.7%.

In terms of validation of blood cadmium analysis, MDL and MQL were 0.07 μg/kg and 0.13 μg/kg respectively in ICP-MS. In calibration curve, good linearity was observed (0.9998). Precision which was calculated through %RSD was 1.32% while recovery was 83.8% ([Fig. 1](#F001){ref-type="fig"}. and [Table 4](#T004){ref-type="table"}).

###### 

Method validation of Pb and Cd in blood by ICP-MS

  ----------------- --------------------- ----------------------
  Blood             Pb                    Cd
                                          
  MDL               0.55 (μg/d*l*)        0.07 (μg/kg)
  MQL               1.10 (μg/d*l*)        0.13 (μg/kg)
  Linear equation   y = 16079x + 237058   y = 6285.5x + 3436.5
  R^2^              0.9993                0.9998
  Precision (%)     1.23                  1.32
  Recovery (%)      90.7                  83.8
  ----------------- --------------------- ----------------------

###### 

Method validation of Pb and Cd in serum by ICP-MS

  ----------------- -------------------- ---------------------
  Serum             Pb                   Cd
                                         
  MDL               0.10 (μg/d*l*)       0.07 (μg/kg)
  MQL               0.21 (μg/d*l*)       0.14 (μg/kg)
  Linear equation   y = 16159x + 42293   y = 6089.5x + 231.7
  R^2^              0.9975               0.9998
  Precision (%)     1.82                 2.40
  Recovery (%)      90.7                 87.3
  ----------------- -------------------- ---------------------

***Validation of analysis methods of serum lead and cadmium.*** First of all, in terms of the validation of serum lead level analysis, MDL was 0.10 μg/d*l* while MQL was 0.21 μg/d*l* in ICP-MS. In terms of calibration curve, good linearity was observed (0.9975). Precision which was calculated through %RSD was 1.82% while recovery was 90.7%.

In terms of validation of serum cadmium analysis, MDL and MQL were 0.07 μg/kg and 0.14 μg/kg respectively in ICP-MS. In calibration curve, good linearity was observed (0.9998). Precision which was calculated through %RSD was 2.40% while recovery was 87.3% ([Fig. 2](#F002){ref-type="fig"}. and [Table 5](#T005){ref-type="table"}).

***Validation of analysis methods of blood and serum mercury.*** For validation of the analysis method on mercury levels in the blood and serum, Gold amalgamation has been used. Because this method doest not require pre-treatment process, it can reduce analyzing time and eliminate the possibility of pollution or loss caused by the pre-treatment.

In blood, LOD and LOQ were 0.62 ng/g and 1.24 ng/g respectively. Good linearity was observed with 0.9993. Precision which was calculated through %RSD was 3.82% while recovery was 82.8% . In serum, LOD and LOQ were 0.22 ng/g and 0.44 ng/g respectively. Good linearity was observed with 0.9993. Precision which was calculated through %RSD was 6.84%. As a result, validation has been verified ([Fig. 3](#F003){ref-type="fig"} and [Table 6](#T006){ref-type="table"}).

![Calibration curve of Pb and Cd in serum by ICP-MS.](toxicr-28-93-g002){#F002}

![Calibration curve of Hg by gold amalgamation.](toxicr-28-93-g003){#F003}

###### 

Method Validation of Hg in Blood and Serum by Gold amalgamation

  ----------------- ---------------------- ------
  Hg                Gold amalgamation      
                                           
  Blood             Serum                  
                                           
  LOD (μg/kg)       0.62                   0.22
  LOQ (μg/kg)       1.24                   0.44
  Linear equation   y = 0.0235x - 0.0001   
  R^2^              0.9993                 
  Precision (%)     3.82                   6.84
  Recovery (%)      82.8                   \-
  ----------------- ---------------------- ------

***Results of the analysis of Certified Reference Material (CRM).*** Using the certified ICP-MS and Gold amalgamation, the certified reference material (CRM) was analyzed. In terms of CRM, Biorad (California, USA)'s Lyphochel Whole Blood Metals Control Level 1 was used.

According to the analysis on the CRM, lead, cadmium and mercury were 9.01 μg/d*l*, 4.96 μg/kg and 5.67 ng/g respectively. All materials were within the scope of the reference value ([Table 7](#T007){ref-type="table"}).

###### 

Result of certified reference material in blood

  ----------------- -------------- -------------- -----------------
                    Pb (μg/d*l*)   Cd (μg/kg)     Hg (μg/kg)
                                                  
  Institute         Biorad whole   blood metals   control Level-1
  Result            9.01           4.96           5.67
  Reference value   9.58 ± 1.91    5.13 ± 1.02    6.85 ± 1.37
  ----------------- -------------- -------------- -----------------

***Analysis of heavy metal levels in the blood and serum among the patients with Alzheimer's diseases.*** Using the certified ICP-MS and Gold amalgamation, the blood and serum lead, cadmium and mercury levels among elderly people were analyzed.

The exposure to heavy metal was investigated against a control group (130 people) and Alzheimer's disease group (80 patients). According to the investigation, a control group was 2.19 μg/d*l* while Alzheimer's disease group was 1.90 μg/ d*l* in terms of the blood lead levels. In terms of blood cadmium levels, a control group and Alzheimer's disease group were 1.06 μg/kg and 1.12 μg/kg respectively. In terms of blood mercury levels, on the contrary, a control group and Alzheimer's disease group were 3.23 μg/g and 2.93 μg/g respectively.

In terms of serum lead levels, a control group was 0.17 μg/d*l* while Alzheimer's disease group was 0.20 μg/d*l*. In terms of serum cadmium levels, both control group and Alzheimer's disease group were 0.07 μg/kg (LOD) or below. In terms of serum mercury levels, a control group and Alzheimer's disease group were 1.43 μg/g and 1.45 μg/g respectively.

###### 

Comparison of blood heavy metal level between normal group and Alzheimer disease group

  --------------- --------------- --------- ------- -------- --------------- ------ ------ ------------ -----
  Blood           Average         Geomean   Stedv   Median   95 percentile   Min    Max    Count (ea)   
                                                                                                        
  Pb^\*^          Control group   2.19      1.99    0.94     1.99            3.96   0.48   4.96         130
  Patient group   1.90            1.68      0.97    1.79     3.73            0.38   5.92     80         
  Cd^\*\*^        Control group   1.06      0.98    0.46     0.97            1.99   0.32   2.59         130
  Patient group   1.12            0.98      0.58    1.06     2.15            0.12   3.61     80         
  Hg^\*\*^        Control group   3.23      2.79    2.10     2.70            6.94   0.85   13.8         130
  Patient group   2.93            2.55      1.79    2.46     6.73            0.88   9.95     80         
  --------------- --------------- --------- ------- -------- --------------- ------ ------ ------------ -----

^\*^μg/d*l*, ^\*\*^μg/kg, control group: the normal aged, patient group: the aged with Alzheimer's disease.

###### 

Comparison of serum heavy metal level between normal group and Alzheimer disease group

  --------------- --------------- --------- ------- -------- --------------- ------- ------- ------------ -----
  Serum           Average         Geomean   Stedv   Median   95 percentile   Min     Max     Count (ea)   
                                                                                                          
  Pb^\*^          Control group   0.17      0.14    0.12     0.13            0.39    0.041   0.69         130
  Patient group   0.20            0.14      0.27    0.13     0.54            0.036   2.12      80         
  Cd^\*\*^        Control group   \< ND     \-      \< ND    \< ND           \< ND   0       0.13         130
  Patient group   \< ND           \-        \< ND   \< ND    \< ND           0       0.16      80         
  Hg^\*\*^        Control group   1.43      1.27    0.89     1.295           2.54    0.30    8.44         130
  Patient group   1.45            1.31      0.77    1.29     2.45            0.48    4.91      80         
  --------------- --------------- --------- ------- -------- --------------- ------- ------- ------------ -----

^\*^μg/d*l*, ^\*\*^μg/kg, control group: the normal aged, patient group: the aged with Alzheimer's disease.

In terms of blood lead and mercury levels, a control group was higher than Alzheimer's disease group. In terms of blood cadmium levels, on the contrary, Alzheimer's disease group was higher than a control group. In case of serum, however, serum cadmium levels were LOD or below. In terms of serum lead and mercury levels, Alzheimer's disease group was higher than a control group ([Tables 8](#T008){ref-type="table"}, [9](#T009){ref-type="table"}).

***Analysis of correlations between heavy metal and Alzheimer's disease.*** Based on an analysis on the exposure to heavy metal against a control group (130 people) and Alzheimer's disease group (80 patients), the correlations between heavy metal and Alzheimer's disease were investigated. To analyze the correlations, t-test was performed with the hypothesis that if the p-value was ≤ 0.05, the sample results were deemed statistically significant.

According to the analysis of correlations between blood heavy metal levels and Alzheimer's disease, lead, cadmium and mercury were 0.035, 0.43 and 0.27 respectively in terms of p-value. In case of serum, lead, cadmium and mercury were 0.45, 0.24 and 0.9 respectively in terms of p-value.

To analyze correlations between blood and serum heavy metal levels and Alzheimer's disease, t-test was performed. Even though correlations were observed between the blood lead levels and Alzheimer's disease (p-value = 0.035), they were not statistically significant because a control group was higher than Alzheimer's group in terms of concentration levels. No statistical significance was found in both cadmium and mercury. In case of serum, no statistical significance was observed between heavy metals (lead, cadmium and mercury) and Alzheimer's disease ([Table 10](#T010){ref-type="table"}).

###### 

Correlations of heavy metal level in blood and serum

  -------- --------- ---------
  Matrix   Element   p-value
                     
  Blood    Pb        0.035
  Cd       0.43      
  Hg       0.27      
  Serum    Pb        0.45
  Cd       0.24      
  Hg       0.9       
  -------- --------- ---------

DISCUSSION
==========

In this study, validation by analysis method was tested using ICP-MS and Gold amalgamation in order to analyze heavy metals using the blood and serum of patients with Alzheimer's disease and find out correlations between heavy metals and Alzheimer's disease. In addition, head, cadmium and mercury were compared between a control group and Alzheimer's disease group.

For analysis of lead and cadmium levels in the blood and serum, ICP-MS was obtained in terms of good linearity, precision, MDL, MQL and recovery. Therefore, it was applied to the samples.

To analyze mercury levels in the blood and serum, the Gold-amalgamated Direct Mercury Analyzer was used. As a result, good linearity, precision, recovery and LOD were obtained.

According to the analysis of lead, cadmium and mercury levels in blood. In terms of cadmium concentration levels, Alzheimer's disease group was higher than a control group.

In terms of the serum cadmium levels, both control group and patient group were 0.07 μg/kg (LOD) or below. In terms of lead and mercury levels in the serum, a control group was higher than Alzheimer's disease group.

For analysis of correlations between heavy metals in the blood and serum and Alzheimer's disease, t-test has been performed. Even though correlations were observed between the blood lead levels and Alzheimer's disease (p-value = 0.035), they were statistically insignificant because the concentration was higher in a control group. No significance was found in Cd and Hg. In the serum, on the other hand, no statistical significance was found between the heavy metal (Pb, Cd and Hg) and Alzheimer's disease.

In this study, no statistical significance was observed between heavy metal and decrease in cognitive intelligence. However, it appears that a further study needs to be performed.
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